TWI262805B - Pharmaceutical composition for treating or inhibiting colonic polyps - Google Patents

Pharmaceutical composition for treating or inhibiting colonic polyps

Info

Publication number
TWI262805B
TWI262805B TW090105702A TW90105702A TWI262805B TW I262805 B TWI262805 B TW I262805B TW 090105702 A TW090105702 A TW 090105702A TW 90105702 A TW90105702 A TW 90105702A TW I262805 B TWI262805 B TW I262805B
Authority
TW
Taiwan
Prior art keywords
treating
pharmaceutical composition
colonic polyps
inhibiting colonic
inhibiting
Prior art date
Application number
TW090105702A
Other languages
English (en)
Inventor
Philip Frost
Carolyn M Discafani-Marro
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of TWI262805B publication Critical patent/TWI262805B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
TW090105702A 2000-03-13 2001-03-12 Pharmaceutical composition for treating or inhibiting colonic polyps TWI262805B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52419600A 2000-03-13 2000-03-13

Publications (1)

Publication Number Publication Date
TWI262805B true TWI262805B (en) 2006-10-01

Family

ID=24088181

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090105702A TWI262805B (en) 2000-03-13 2001-03-12 Pharmaceutical composition for treating or inhibiting colonic polyps

Country Status (23)

Country Link
EP (1) EP1263503B1 (zh)
JP (1) JP2003526686A (zh)
KR (2) KR100817423B1 (zh)
CN (1) CN1190197C (zh)
AR (1) AR035482A1 (zh)
AT (1) ATE308364T1 (zh)
AU (2) AU4545201A (zh)
BR (1) BR0109165A (zh)
CA (1) CA2402742C (zh)
DE (1) DE60114580T2 (zh)
DK (1) DK1263503T3 (zh)
EA (1) EA200200976A1 (zh)
ES (1) ES2248302T3 (zh)
HK (1) HK1048775B (zh)
HU (1) HUP0300547A2 (zh)
IL (2) IL151249A0 (zh)
MX (1) MXPA02008836A (zh)
NO (1) NO20024356L (zh)
NZ (1) NZ521117A (zh)
PL (1) PL202873B1 (zh)
TW (1) TWI262805B (zh)
WO (1) WO2001068186A2 (zh)
ZA (1) ZA200208178B (zh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
US8367824B2 (en) * 2002-01-28 2013-02-05 Ube Industries Ltd. Process for producing quinazolin-4-one derivative
WO2003066575A1 (en) 2002-02-05 2003-08-14 Wyeth Process for the synthesis of n-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids
JP2005536462A (ja) * 2002-04-30 2005-12-02 ユン ジン ファーマスーチカル インダストリーズ カンパニー リミテッド カスパーゼ−３阻害剤としてのキノリン誘導体、この製造方法及びこれを含む薬剤学的組成物
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL379330A1 (pl) 2002-12-20 2006-08-21 Pfizer Products Inc. Pochodne pirymidyny dla leczenia nienormalnego wzrostu komórek
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
EP1673085B1 (en) 2003-09-26 2011-11-09 Exelixis, Inc. C-met modulators and methods of use
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
MXPA06013164A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
BRPI0510963A (pt) 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
WO2005111024A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
BRPI0610142A2 (pt) * 2005-05-25 2011-01-04 Wyeth Corp método para preparar um composto da fórmula (i) ; e método para preparar um ácido da fórmula (vii)
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
DE102006029445A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-Cyano-chinoline als Kinase-Inhibitoren
DE102006029446A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-substituierte-Chinoline als Kinase-Inhibitoren
BRPI0717586A2 (pt) 2006-09-18 2013-10-29 Boehringer Ingelheim Int Método para tratar câncer apresentando mutações do egfr
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
KR101733773B1 (ko) 2009-01-16 2017-05-10 엑셀리시스, 인코포레이티드 Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
AU2010265932B2 (en) 2009-06-25 2014-11-20 Amgen Inc. Heterocyclic compounds and their uses
DK2451445T3 (da) 2009-07-06 2019-06-24 Boehringer Ingelheim Int Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
JP6533997B2 (ja) * 2014-12-26 2019-06-26 株式会社ヤクルト本社 Ｚｎｆ１４３阻害活性を有する化合物およびその利用
US10246424B2 (en) * 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
AU2016355433C1 (en) 2015-11-16 2021-12-16 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
KR20200010306A (ko) 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Kras의 공유적 억제제
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
US10736897B2 (en) 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
BR0013219A (pt) * 1999-08-12 2002-04-23 American Cyanamid Co Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto

Also Published As

Publication number Publication date
EA200200976A1 (ru) 2003-02-27
AU4545201A (en) 2001-09-24
NO20024356D0 (no) 2002-09-12
DE60114580T2 (de) 2006-07-27
HUP0300547A2 (hu) 2003-07-28
AR035482A1 (es) 2004-06-02
IL151249A0 (en) 2003-04-10
CN1190197C (zh) 2005-02-23
ES2248302T3 (es) 2006-03-16
EP1263503A2 (en) 2002-12-11
WO2001068186A2 (en) 2001-09-20
HK1048775B (zh) 2006-01-20
MXPA02008836A (es) 2003-02-10
KR20020092987A (ko) 2002-12-12
DE60114580D1 (de) 2005-12-08
DK1263503T3 (da) 2006-02-13
BR0109165A (pt) 2003-04-22
KR100817423B1 (ko) 2008-03-27
JP2003526686A (ja) 2003-09-09
CA2402742A1 (en) 2001-09-20
EP1263503B1 (en) 2005-11-02
ZA200208178B (en) 2004-02-11
WO2001068186A3 (en) 2002-01-17
IL151249A (en) 2008-06-05
ATE308364T1 (de) 2005-11-15
CA2402742C (en) 2009-05-12
HK1048775A1 (en) 2003-04-17
KR20080009294A (ko) 2008-01-28
NZ521117A (en) 2005-02-25
AU2001245452B2 (en) 2005-05-05
CN1429126A (zh) 2003-07-09
NO20024356L (no) 2002-11-12
PL363072A1 (en) 2004-11-15
PL202873B1 (pl) 2009-07-31

Similar Documents

Publication Publication Date Title
TWI262805B (en) Pharmaceutical composition for treating or inhibiting colonic polyps
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
WO2003082205A3 (en) Compounds and methods
PL344861A1 (en) Trazinic angiogenesis inhibitiors
MXPA05012837A (es) Inhibidores de caspasa y usos de los mismos.
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
DE60112330D1 (en) Pyrazolopyridinderivate
HK1085675A1 (en) Anticancer compounds
AP2002002616A0 (en) Antidibetic agents
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
MXPA04006041A (es) Antivirales de piridoquinoxalina.
EE200000472A (et) Kasvajavastased toimeained
AU2003223340A8 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
AP2002002387A0 (en) Method of inhibiting amyloid aggregation and imaging amyloid deposits.
IL157540A (en) Pharmaceutical compositions comprising n-(aryl)-2-arylethenesulfonamides, some such novel compounds and process for their preparation
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
WO2003080631A8 (en) Plasma carboxypeptidase b inhibitors
DE60135752D1 (en) Tyrosinderivate als phosphatase inhibitoren
HK1061355A1 (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
WO2002098399A3 (en) Cancer treatment method and compositions comprising compounds of the ginger family
UA85994C2 (en) N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives
ZA200400824B (en) Pyridin-2-yl-methlyamine derivatives for treating opioid dependence.